Penn Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Penn Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$841K	Buy	+5,506	New	+$668K	0.05%	128

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Penn Capital Management's PVLA Position: Q2 2026 in Review

Penn Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 5,506 shares worth $841K. The stake represents 0.05% of the portfolio and ranks #128 among its holdings.

196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Penn Capital Management held 5,506 shares of Palvella Therapeutics worth $841K as of Q2 2026.
Palvella Therapeutics was a new Penn Capital Management position in Q2 2026.
Palvella Therapeutics made up 0.05% of Penn Capital Management's portfolio in Q2 2026, its #128 holding.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.